We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $163M
1-Year Est. Return 240.43%
This Fund
S&P 500
This Quarter Est. Return
-3.19%
1 Year Est. Return
+240.43%
3 Year Est. Return
+409.28%
5 Year Est. Return
+142.09%
10 Year Est. Return
+4,071.98%
AUM
$95M
AUM Growth
-$36.3M
Cap. Flow
-$17.3M
Cap. Flow %
-18.23%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$16.5M
2
OPGN
OpGen, Inc
OPGN
+$791K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLD
1
DELISTED
Audentes Therapeutics, Inc
BOLD
$37.6M 39.61%
1,204,615
-602,217
-33% -$16.5M
AKAO
2
DELISTED
Achaogen Inc
AKAO
$13.8M 14.48%
1,281,152
– –
OCUL icon
3
Ocular Therapeutix
OCUL
$2.35B
$9.86M 10.37%
2,215,384
– –
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$9.65M 10.15%
1,048,601
– –
IMDZ
5
DELISTED
Immune Design Corp.
IMDZ
$8.61M 9.06%
2,208,210
– –
VANI icon
6
Vivani Medical
VANI
$115M
$8.58M 9.03%
187,207
– –
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
$6.93M 7.29%
101,855
– –
OPGN
8
DELISTED
OpGen, Inc
OPGN
– –
-26
Closed -$791K

Similar funds

TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
GF
Gimbal Financial Carmel, Indiana $163M AUM
ACM
Arrington Capital Management Miami, Florida $163M AUM
KFS
Krane Financial Solutions Calabasas, California $162M AUM
VB
Value Base Tel Aviv, Israel $162M AUM 2.31% 1-Year Est. Return
RWA
Reicon Wealth Advisors Atlanta, Georgia $162M AUM
CCM
Candelo Capital Management New York $162M AUM 112.87% 1-Year Est. Return
GCM
Generation Capital Management Pittsford, New York $163M AUM 42.22% 1-Year Est. Return

Versant Venture Management's Q4 2017 Portfolio in Review

As of Q4 2017, Versant Venture Management held 8 positions worth $95M, down 28% from $131M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $17.3M in Q4 2017, closing 1 position and reducing 1 holding. Its most notable exit was OpGen, Inc, an estimated $791K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management's biggest Q4 2017 reduction was Audentes Therapeutics, Inc, cutting an estimated $16.5M.
  • Versant Venture Management fully exited OpGen, Inc in Q4 2017, selling an estimated $791K.
  • Versant Venture Management's ten largest holdings make up 100% of its $95M portfolio in Q4 2017.
  • Versant Venture Management opened 0 new positions and closed 1 in Q4 2017.
  • Versant Venture Management's portfolio value fell 28% quarter-over-quarter to $95M.

Based on Versant Venture Management's 13F filing for Q4 2017, filed 25 Jan 2018.